But the full P2 trial was scheduled to start this quarter. Now it won't happen until they have more mouse data and any results from the expanded access case, which the FDA explicitly state the expanded-access program is not to be used for any kind of safety or efficacy evaluation as it is just 1 patient. So if the trial gets off the ground before the end of the year it will be a miracle
They were supposed to be starting P2 trials in Q2 for MS and Crohn's. Now they won't be and any data will not be before the end of the year, which presumably would be from a Covid study
Seem like a couple of nice guys but that was a disaster. Going backwards. No chance of getting anything to market for at least 6-7 years. Can forget about the C19 trial. No mention of it. As per last RNS still at the planning stage
MS P2 trial was supposed to be starting in the summer but now won't be for at least another 6 months because they have screwed up with the pre clinical